⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 1, 2024Cell Reports MedicineOpen Access

Chemoradiotherapy-induced ACKR2+ tumor cells drive CD8+ T cell senescence and cervical cancer recurrence

Dongfang Dai Yifei Pei Biqing Zhu Deqiang Wang Siyu Pei Huan Huang Qingchen Zhu Xiuyu Deng Jialin Ye Jing Xu Xiaoxiang Chen Mingzhu Huang Yichuan Xiao

View Full Paper

Ask AI

Bookmark

Share

Abstract

Tumor recurrence after chemoradiotherapy is challenging to overcome, and approaches to predict the recurrence remain elusive. Here, human cervical cancer tissues before and after concurrent chemoradiotherapy (CCRT) analyzed by single-cell RNA sequencing reveal that CCRT specifically promotes CD8

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dai et al. (2024) studied this question.

synapsesocial.com/papers/68e6c02bb6db64358763f531 https://doi.org/10.1016/j.xcrm.2024.101550

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Targeting radiation induced CD4 CCR8 T cells enhances anti-tumor immunity and reduces recurrence in Head and Neck Squamous Cell Carcinoma 93822025
2Radiotherapy‐Associated Cellular Senescence and EMT Alterations Contribute to Distinct Disease Relapse Patterns in Locally Advanced Cervical CancerOriginal Research · 2025 · 14 citations
3Chemoradiotherapy facilitates siglec-10+/siglec-9+ macrophage-mediated impairment of CD24+/MUC16+ tumor cell elimination and enhances PD-L2 dependent immunosuppression in cervical cancerOriginal Research · 2026 · 1 citations
4Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical CancerLongitudinal Study · 2026 · 2 citations
5Stress-resolved longitudinal single-cell and spatial transcriptomic analysis supports a tumor–immune remodeling framework during chemoradiotherapy in cervical cancerCross-Sectional Study · 2026

More related papers

Transcriptomic Profiling Reveals Predictive Markers of Response to Concurrent Chemoradiotherapy plus Immune Checkpoint Inhibition in Cervical Cancer2025
Immune Predictors of Radiotherapy Outcomes in Cervical Cancer2026
An In-Field Recurrent Cervical Cancer Case After Chemoradiotherapy With a Marked Response to Pembrolizumab Combined With TC (Paclitaxel-Carboplatin) Therapy: A Case Report2026

More from Cell Reports Medicine

Multi-omics-driven personalized management of advanced HCCThu,
Enhanced liver regeneration via targeted mRNA delivery for partial in vivo reprogrammingThu,